MedTrace Logo

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease

NCT02556021 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 324

Last updated 2018-04-04

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the superiority of efficacy of CJ-12420, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4

Conditions

  • Non-erosive Reflux Disease

Interventions

DRUG

CJ-12420 50mg

CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks

DRUG

CJ-12420 100mg

CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks

DRUG

Placebo

Placebo, tablet, once daily, oral administration for up to 4 weeks

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-22
Primary Completion
2016-11-01
Completion
2016-11-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02556021 on ClinicalTrials.gov